GTS Securities LLC Buys New Position in Novartis AG $NVS

GTS Securities LLC bought a new stake in Novartis AG (NYSE:NVS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,897 shares of the company’s stock, valued at approximately $611,000.

Several other hedge funds also recently made changes to their positions in NVS. Morgan Stanley raised its holdings in shares of Novartis by 14.9% in the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after purchasing an additional 1,148,033 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in Novartis by 3.1% during the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock worth $1,029,317,000 after purchasing an additional 226,484 shares during the last quarter. Bank of America Corp DE boosted its holdings in Novartis by 9.1% during the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after purchasing an additional 413,778 shares during the last quarter. Auto Owners Insurance Co grew its position in Novartis by 13,687.0% in the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after purchasing an additional 4,594,726 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Novartis by 10.3% in the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock valued at $617,562,000 after buying an additional 419,988 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Price Performance

NYSE:NVS opened at $153.75 on Monday. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The firm has a fifty day simple moving average of $155.07 and a 200 day simple moving average of $153.76. The stock has a market capitalization of $293.38 billion, a PE ratio of 23.19, a P/E/G ratio of 2.64 and a beta of 0.45.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. On average, research analysts expect that Novartis AG will post 8.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Citigroup restated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Novartis presently has an average rating of “Hold” and an average price target of $141.20.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.